Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Glioma Assessment

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has emerged as a pivotal tool for characterising the vascular architecture and permeability of gliomas. By tracking the temporal distribution of gadolinium-based contrast agents within tumour tissue, DCE-MRI quantifies parameters such as the volume transfer constant (Ktrans) and the extravascular extracellular volume fraction (Ve). These metrics provide insight into neoangiogenesis, blood–brain barrier disruption and extracellular space expansion that underpin tumour aggressiveness and heterogeneity. In clinical practice, DCE-MRI enhances tumour grading, differentiates glioma subtypes, predicts prognosis and guides treatment planning. Integration with machine-learning algorithms and multiparametric imaging has further refined delineation of residual disease, assessment of treatment response and early detection of recurrence. As glioma management moves towards personalised medicine, DCE-MRI offers non-invasive biomarkers for stratifying patients, optimising radiotherapy targets and evaluating novel anti-angiogenic and immunotherapeutic strategies on a global scale.

Research from Nature Portfolio

Recent studies have demonstrated the added value of incorporating DCE-MRI parameters into deep learning models for predicting local recurrence in high-grade diffuse gliomas. By combining conventional MRI sequences with quantitative maps of Ktrans and Ve, a neural network framework achieved significantly higher sensitivity for detecting subtle areas of neoangiogenesis within non-enhancing T2 hyperintensities. The improved detection rates offer promise for risk-adapted radiotherapy planning, enabling clinicians to tailor dose escalation to regions at greatest risk of residual tumour, potentially reducing missed recurrences without substantially compromising specificity.

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Glioma Assessment publication trend

The graph below shows the total number of articles in dynamic contrast-enhanced magnetic resonance imaging in glioma assessment across all publications each year (not limited to Nature Index journals).

Technical terms

Dynamic Contrast-Enhanced MRI (DCE-MRI): A perfusion imaging technique that acquires rapid T1-weighted sequences during and after intravenous contrast administration to assess microvascular leakage and blood flow dynamics.

Ktrans: The volume transfer constant representing the rate at which contrast agent moves from the vascular compartment into the extravascular extracellular space, reflecting vessel permeability.

Ve: The fractional volume of the extravascular extracellular space per unit tissue volume, indicating the size of the space available for contrast distribution outside vessels.

Initial Area Under Gadolinium Concentration Curve (IAUGC): The integrated concentration of contrast agent over an early post-injection time window, serving as a composite measure of perfusion and permeability.

Neoangiogenesis: The process of new blood vessel formation within the tumour microenvironment, contributing to increased permeability and altered haemodynamics detectable by DCE-MRI.

References

1. Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives. Biomarker Research (2023).
2. Advances in the Radiological Evaluation of and Theranostics for Glioblastoma. Cancers (2023).
3. Added value of dynamic contrast-enhanced MR imaging in deep learning-based prediction of local recurrence in grade 4 adult-type diffuse gliomas patients. Scientific Reports (2024).
4. Clinical Applications of Contrast‐Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges. Contrast Media & Molecular Imaging (2017).